- 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
- 4DMT to Participate in Upcoming Investor Conferences
- 4DMT Reports Full Year 2023 Financial Results and Operational Highlights
- 4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
- 4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
- 4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
- 4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
- 4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
- 4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
- 4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
More ▼
Key statistics
On Thursday, 4D Molecular Therapeutics Inc (FDMT:NSQ) closed at 23.53, -35.09% below its 52-week high of 36.25, set on Mar 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.51 |
---|---|
High | 23.98 |
Low | 22.91 |
Bid | 18.90 |
Offer | 37.41 |
Previous close | 23.53 |
Average volume | 485.45k |
---|---|
Shares outstanding | 51.16m |
Free float | 49.35m |
P/E (TTM) | -- |
Market cap | 1.20bn USD |
EPS (TTM) | -2.58 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 21:00 BST.
More ▼